{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Vulvar+Cancer&page=2", "query": { "condition": "Recurrent Vulvar Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Vulvar+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:07:13.328Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00106262", "title": "Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Velcade (bortezomib)", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Women and Infants Hospital of Rhode Island", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 38, "start_date": "2005-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2007-04-18", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106262" }, { "nct_id": "NCT00335998", "title": "Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Cervical Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Stage III Vaginal Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Vulvar Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Vulvar Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Vulvar Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer" ], "interventions": [ { "name": "triapine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335998" }, { "nct_id": "NCT00900302", "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 98, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900302" }, { "nct_id": "NCT03260023", "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HPV-Related Carcinoma", "HPV-Related Cervical Carcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "TG4001", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Transgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2017-09-01", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260023" }, { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" }, { "nct_id": "NCT00003525", "title": "Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer Stage IV", "Vulvar Cancer, Stage IV" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 8, "start_date": "1996-06-03", "completion_date": "1998-01-22", "has_results": false, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003525" }, { "nct_id": "NCT03987555", "title": "Paclitaxel Therapeutic Drug Monitoring in Cancer Patients", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor, Adult", "Metastatic Nonsmall Cell Lung Cancer", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Cervical Carcinoma", "Metastatic Ovarian Carcinoma", "Malignant Uterine Neoplasm", "Vulvar Cancer", "Invasive Breast Cancer", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Vulvar Carcinoma", "Stage IV Cervical Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vulva Squamous Cell Carcinoma" ], "interventions": [ { "name": "Blood draws", "type": "OTHER" }, { "name": "QLQ-CIPN20 Survey", "type": "OTHER" }, { "name": "PR-CTCAE Survey", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-11-11", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03987555" }, { "nct_id": "NCT00897442", "title": "Collecting Tumor Samples From Patients With Gynecological Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Borderline Ovarian Clear Cell Tumor", "Borderline Ovarian Serous Tumor", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Small Cell Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Childhood Embryonal Rhabdomyosarcoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Endometrioid Stromal Sarcoma", "Gestational Trophoblastic Tumor", "Malignant Mesothelioma", "Malignant Ovarian Epithelial Tumor", "Melanoma", "Neoplasm of Uncertain Malignant Potential", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Paget Disease of the Vulva", "Recurrent Cervical Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Cervical Cancer", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage III Cervical Cancer", "Stage III Uterine Corpus Cancer", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IV Uterine Corpus Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Uterine Corpus Cancer", "Uterine Corpus Leiomyosarcoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 275, "start_date": "1992-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 187, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897442" }, { "nct_id": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papillomavirus-Related Carcinoma", "Human Papillomavirus Positive Oropharyngeal Carcinoma", "Human Papillomavirus Positive Cervical Carcinoma", "Human Papillomavirus Positive Anal Carcinoma", "Human Papillomavirus Positive Vulvar Carcinoma", "Human Papillomavirus Positive Penile Carcinoma" ], "interventions": [ { "name": "HPV Specific T Cells", "type": "GENETIC" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "DRUG", "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-09", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02379520" }, { "nct_id": "NCT02786524", "title": "Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Uterine Cervical Neoplasms", "Ovarian Neoplasms", "Gynecologic Neoplasms", "Fallopian Tube Neoplasms", "Vulvar Neoplasms", "Vaginal Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Specialized Symptom Management and Supportive Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2016-02-15", "completion_date": "2017-10-31", "has_results": false, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-06-11T04:07:13.328Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02786524" } ] }